Acceder

Farmas USA

136K respuestas
Farmas USA
85 suscriptores
Farmas USA
Página
15.968 / 17.032
#127737

Re: Farmas USA

Amarin highlights clinical benefits of Vascepa with presentation of new study

Mar. 17, 2021 12:00 PM ETAmarin Corporation plc (AMRN)By: Dulan Lokuwithana, SA News Editor7 Comments
  • A new analysis supported by Amarin Corporation (AMRN +1.1%) and presented at the ongoing International Stroke Conference 2021 highlights the clinical impact of VASCEPA® (icosapent ethyl), the company said.
  • The presentation of REDUCE-IT® STROKE as announced by HLS Therapeutics (OTCPK:HLTRF) includes an analysis of the stroke rates across the enrolled patient population (n=8179).
  • Event rates for time to first fatal or nonfatal stroke: 2.4% for VASCEPA vs. 3.3% for placebo with a relative risk reduction (“RRR”) of 28% (p=0.01).
  • Ischemic stroke time to first event rates: 2.0% for VASCEPA vs. 3.0% for placebo at a RRR of 36% (p=0.002).
  • However, there was no significant difference between VASCEPA vs. placebo (0.3% vs 0.2%; p=0.55) for hemorrhagic stroke which occurred at low rates.
  • VASCEPA, sales of which rose at a record ~17% YoY in Q4 2020 is approved in the U.S., Canada, Lebanon, and the UAE.

#127738

Re: Farmas USA

TEVA
Vaya Pullback desde los 11 tocados 11.59
Haber si aguantan esos 11.50 dependera de la FED
#127741

Re: Farmas USA

SRPT

Esta tiene que estar a punto de dar alguna alegría a no mucho tardar.

He entrado hoy a 84 largos por cierto.






#127743

Re: Farmas USA

Estoy muy de petas últimamente! Jajajajajajaja
#127744

Re: Farmas USA

AMRN
Si esto no es un cruce de la muerte alcista, se le parece mucho. Tras el corte tiene que subir para confirmarlo.

Si te sientas en la mesa y no descubres al "primo" es que lo eres tú.

Te puede interesar...
  1. Primeras dudas sobre la 'Trumponomics', ¿corrección o toma de beneficios?
  2. Nvidia bate expectativas pero decepciona. Insiders reafirman su posición